Intensive LOwering of BlOod low-density lipoprotein ChOlesterol with statin + ezetimibe therapy improves cardiac function after Percutaneous coronary intervention in patients with coronary stenting in Fukuoka-II (LOBOCOP-II)

Trial Profile

Intensive LOwering of BlOod low-density lipoprotein ChOlesterol with statin + ezetimibe therapy improves cardiac function after Percutaneous coronary intervention in patients with coronary stenting in Fukuoka-II (LOBOCOP-II)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Atorvastatin (Primary) ; Ezetimibe (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms LOBOCOP-II
  • Most Recent Events

    • 29 Mar 2012 Results presented at the 16th International Symposium on Atherosclerosis.
    • 18 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 13 Sep 2011 Planned End Date changed from 1 Mar 2011 to 1 Dec 2011 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top